Rejencia

Rejencia Therapeutics is a private biotechnology company headquartered in San Diego, California, dedicated to the discovery and development of novel small molecule drugs for oncology. The company focuses on targeting high-value, previously undruggable proteins, specifically transcription factors and protein-protein interactions that are central to cancer cell survival and proliferation. By leveraging its proprietary drug discovery platform, Rejencia aims to create potent and selective inhibitors for these challenging targets, providing new therapeutic options for patients with difficult-to-treat malignancies. The company is currently in the pre-clinical stage of development with a pipeline of programs focused on solid tumors. Rejencia is supported by leading venture capital firms, including F-Prime Capital and Eight Roads Ventures.